Email Updates

Search form

You are here

Safety and Immunogenicity of a Multivalent HIV Vaccine Comprising Envelope Protein With Either DNA or NYVAC Vectors (HVTN 096): A Phase 1b, Double-Blind, Placebo-Controlled Trial

Include in
Published Research

Co-administration of gp120 Env protein components with DNA or NYVAC vectors during priming led to early and potent induction of Env V1/V2 IgG binding antibody responses. This immunisation approach should be considered for induction of preventive antibodies in future HIV vaccine efficacy trials.

October 7, 2019
Lancet HIV